Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Oct 7;2009(4):CD006627.
doi: 10.1002/14651858.CD006627.pub2.

Ziprasidone versus other atypical antipsychotics for schizophrenia

Katja Komossa  1 , Christine Rummel-Kluge, Heike Hunger, Sandra Schwarz, Paranthaman Seth S Bhoopathi, Werner Kissling, Stefan Leucht
Affiliations
Meta-Analysis

Ziprasidone versus other atypical antipsychotics for schizophrenia

Katja Komossa et al. Cochrane Database Syst Rev. .

Abstract

Background: In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation antipsychotics differ is a matter of debate. In this review we examined how the efficacy and tolerability of ziprasidone differs from that of other second generation antipsychotics.

Objectives: To evaluate the effects of ziprasidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses.

Search strategy: We searched the Cochrane Schizophrenia Group Specialised Register (April 2007) and references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information.

Selection criteria: We included all randomised, at least single-blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia-like psychoses.

Data collection and analysis: We extracted data independently. For continuous data, we calculated weighted mean differences (MD) for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate.

Main results: The review currently includes nine randomised controlled trials (RCTs) with 3361 participants. The overall rate of premature study discontinuation was very high (59.1%). Data for the comparisons of ziprasidone with amisulpride, clozapine, olanzapine, quetiapine and risperidone were available. Ziprasidone was a less acceptable treatment than olanzapine (leaving the studies early for any reason: 5 RCTs, n=1937, RR 1.26 CI 1.18 to 1.35, NNH 7 CI 5 to 10) and risperidone (3 RCTs, n=1029, RR 1.11 CI 1.02 to 1.20, NNH 14 CI 8 to 50), but not than the other second generation antipsychotic drugs. Ziprasidone was less efficacious than amisulpride (leaving the study early due to inefficacy: 1 RCT, n=123, RR 4.72 CI 1.06 to 20.98, NNH 8 CI 5 to 50) olanzapine (PANSS total score: 4 RCTs, n=1291, MD 8.32 CI 5.64 to 10.99) and risperidone (PANSS total score: 3 RCTs, n=1016, MD 3.91 CI 0.27 to 7.55). Based on limited data there were no significant differences in tolerability between ziprasidone and amisulpride or clozapine. Ziprasidone produced less weight gain than olanzapine (5 RCTs, n=1659, MD -3.82 CI -4.69 to -2.96), quetiapine (2 RCTs, n=754, RR 0.45 CI 0.28 to 0.74) or risperidone (3 RCTs, n=1063, RR 0.49 CI 0.33 to 0.74). It was associated with less cholesterol increase than olanzapine, quetiapine and risperidone. Conversely ziprasidone produced slightly more extrapyramidal side-effects than olanzapine (4 RCTs, n=1732, RR 1.43 CI 1.03 to 1.99, NNH not estimable) and more prolactin increase than quetiapine (2 RCTs, n=754, MD 4.77 CI 1.37 to 8.16), but less movement disorders (2 RCTs, n=822, RR 0.70 CI 0.51 to 0.97, NNT not estimable) and less prolactin increase (2 RCTs, n=767, MD -21.97 CI -27.34 to -16.60) than risperidone.

Authors' conclusions: Ziprasidone may be a slightly less efficacious antipsychotic drug than amisulpride, olanzapine and risperidone. Its main advantage is the low propensity to induce weight gain and associated adverse effects. However, the high overall rate of participants leaving the studies early limits the validity of any findings.

PubMed Disclaimer

Conflict of interest statement

Katja Komossa ‐ none known. Stefan Leucht ‐ has received speaker/consultancy honoraria from Sanofi‐Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He has received research support from Sanofi‐Aventis and Eli Lilly. Christine Rummel ‐ has received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen‐Cilag, Eli Lilly and Pfizer. Werner Kissling ‐ has received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer. Heike Hunger ‐ none known. Franziska Schmid ‐ none known. Sandra Schwarz ‐ none known. Paranthaman Seth Bhoopathi ‐ none known.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 1 No clinically significant response (as defined by the original studies).
1.2
1.2. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 2 Leaving the study early.
1.3
1.3. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 3 Global State: No clinically important change (as defined by the original studies).
1.4
1.4. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 4 Mental state: 1a. General mental state: PANSS total score (high=poor).
1.5
1.5. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 5 Mental state: 1b. General mental state: BPRS total score (high=poor).
1.6
1.6. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 6 Mental state: 2a. Negative symptoms: no clinically important change (less than 50% PANSS negative subscore reduction).
1.7
1.7. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 7 Mental state: 2b. Negative symptoms: PANSS negative subscore (high=poor).
1.8
1.8. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 8 Adverse effects: 1. At least one adverse effect.
1.9
1.9. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 9 Adverse effects: 2. Cardiac effects ‐ QTc prolongation.
1.10
1.10. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 10 Adverse effects: 3. Extrapyramidal side‐effects.
1.11
1.11. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 11 Adverse effects: 4. Sedation.
1.12
1.12. Analysis
Comparison 1 ZIPRASIDONE versus AMISULPRIDE, Outcome 12 Adverse effects: 5. Weight gain of 7% or more of total body weight.
2.1
2.1. Analysis
Comparison 2 ZIPRASIDONE versus CLOZAPINE, Outcome 1 Leaving the study early.
2.2
2.2. Analysis
Comparison 2 ZIPRASIDONE versus CLOZAPINE, Outcome 2 Mental state: general mental state: PANSS total score (high=poor).
2.3
2.3. Analysis
Comparison 2 ZIPRASIDONE versus CLOZAPINE, Outcome 3 Adverse effects: cardiac effects ‐ QTc prolongation.
3.1
3.1. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 1 No clinically significant response (as defined by the original studies).
3.2
3.2. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 2 Leaving the study early.
3.3
3.3. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 3 Global State: no clinically important change (as defined by the original studies).
3.4
3.4. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 4 Mental state: 1a. General mental state: no clinically important change (less than 30% PANSS total score reduction).
3.5
3.5. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 5 Mental state: 1b. General mental state: PANSS total score (high=poor).
3.6
3.6. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 6 Mental state: 1c. General mental state: no clinically important change (less than 40% BPRS total score reduction).
3.7
3.7. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 7 Mental state: 1d. General mental state: BPRS total score (high=poor).
3.8
3.8. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 8 Mental state: 2. Positive symptoms: PANSS positive subscore (high=poor).
3.9
3.9. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 9 Mental state: 3. Negative symptoms: PANSS negative subscore (high=poor).
3.10
3.10. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 10 General Functioning: 1. No clinically important change (less than 5 points improvement on GAF total score).
3.11
3.11. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 11 General Functioning: 2. GAF total score (high=poor).
3.12
3.12. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 12 General Functioning: 3. QLS total score (Heinrichs‐Carpenter) (high=poor).
3.13
3.13. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 13 Cognitive Functioning: PANSS cognition score (high=poor).
3.14
3.14. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 14 Service use: Number of patients re‐hospitalised.
3.15
3.15. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 15 Adverse effects: 1. At least one adverse effect.
3.16
3.16. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 16 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation.
3.17
3.17. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 17 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms.
3.18
3.18. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 18 Adverse effects: 3a. Cholesterol ‐ abnormally high cholesterol value.
3.19
3.19. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 19 Adverse effects: 3b. Cholesterol ‐ change from baseline in mg/dl.
3.20
3.20. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 20 Adverse effects: 4. Death.
3.21
3.21. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 21 Adverse effects: 5a. Extrapyramidal side‐effects.
3.22
3.22. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 22 Adverse effects: 5b. Extrapyramidal side‐effects.
3.23
3.23. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 23 Adverse effects: 6a. Glucose ‐ abnormally high fasting glucose value.
3.24
3.24. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 24 Adverse effects: 6b. Glucose ‐ change from baseline in mg/dl.
3.25
3.25. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 25 Adverse effects: 7a. Prolactin‐associated side‐effects.
3.26
3.26. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 26 Adverse effects: 7b. Prolactin ‐ change from baseline in ng/ml.
3.27
3.27. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 27 Adverse effects: 8. Sedation.
3.28
3.28. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 28 Adverse effects: 9a. Weight gain.
3.29
3.29. Analysis
Comparison 3 ZIPRASIDONE versus OLANZAPINE, Outcome 29 Adverse effects: 9b. Weight gain ‐ change from baseline in kg.
4.1
4.1. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 1 Leaving the study early.
4.2
4.2. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 2 Mental state: 1. General mental state: PANSS total score (high=poor).
4.3
4.3. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 3 Mental state: 2. Positive symptoms: PANSS positive subscore (high=poor).
4.4
4.4. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 4 Mental state: 3. Negative symptoms: PANSS negative subscore (high=poor).
4.5
4.5. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 5 Service use: Number of patients re‐hospitalised.
4.6
4.6. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 6 Adverse effects: 1. At least one adverse effect.
4.7
4.7. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 7 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation.
4.8
4.8. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 8 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms.
4.9
4.9. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 9 Adverse effects: 3. Cholesterol ‐ change from baseline in mg/dl.
4.10
4.10. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 10 Adverse effects: 4. Death.
4.11
4.11. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 11 Adverse effects: 5. Extrapyramidal side effects.
4.12
4.12. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 12 Adverse effects: 6. Glucose ‐ change from baseline in mg/dl.
4.13
4.13. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 13 Adverse effects: 7a. Prolactin‐associated side‐effects.
4.14
4.14. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 14 Adverse effects: 7b. Prolactin ‐ change from baseline in ng/ml.
4.15
4.15. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 15 Adverse effects: 8. Sedation.
4.16
4.16. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 16 Adverse effects: 9a. Weight gain of 7% or more of total body weight.
4.17
4.17. Analysis
Comparison 4 ZIPRASIDONE versus QUETIAPINE, Outcome 17 Adverse effects: 9b. Weight gain ‐ change from baseline in kg.
5.1
5.1. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 1 No clinically significant response (as defined by the original studies).
5.2
5.2. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 2 Leaving the study early.
5.3
5.3. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 3 Global State: No clinically important change (as defined by the original studies).
5.4
5.4. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 4 Mental State 1a. General Mental State (less than 50% PANSS total reduction).
5.5
5.5. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 5 Mental State 1b. General Mental State: PANSS total score (high=poor).
5.6
5.6. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 6 Mental State 1c. General Mental State: BPRS total score (high=poor).
5.7
5.7. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 7 Mental State 2a. Positive Symptoms: PANSS positive subscore (high=poor).
5.8
5.8. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 8 Mental State 2b. Positive Symptoms: BPRS positive subscore (high=poor).
5.9
5.9. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 9 Mental State 3. Negative Symptoms: PANSS negative subscore (high=poor).
5.10
5.10. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 10 Service use: Number of patients re‐hospitalised.
5.11
5.11. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 11 Adverse effects: 1. At least one adverse effect.
5.12
5.12. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 12 Adverse effects: 2a. Cardiac effects ‐ QTc prolongation.
5.13
5.13. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 13 Adverse effects: 2b. Cardiac effects ‐ QTc abnormalities ‐ change from baseline in ms.
5.14
5.14. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 14 Adverse effects: 3 Cholesterol ‐ change from baseline in mg/dl.
5.15
5.15. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 15 Adverse effects: 4. Death.
5.16
5.16. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 16 Adverse effects: 5a. Extrapyramidal side effects.
5.17
5.17. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 17 Adverse effects: 5b. Extrapyramidal side effects.
5.18
5.18. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 18 Adverse effects: 6. Glucose ‐ change from baseline in mg/dl.
5.19
5.19. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 19 Adverse effects: 7a. Prolactin associated side effects.
5.20
5.20. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 20 Adverse effects: 7b. Prolactin ‐ change from baseline in ng/ml.
5.21
5.21. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 21 Adverse effects: 8. Sedation.
5.22
5.22. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 22 Adverse effects: 9a. Weight gain of 7% or more of total body weight.
5.23
5.23. Analysis
Comparison 5 ZIPRASIDONE versus RISPERIDONE, Outcome 23 Adverse effects: 9b. Weight gain ‐ change from baseline in kg.
6.1
6.1. Analysis
Comparison 6 ZIPRASIDONE versus OLANZAPINE ‐ sensitivity analysis (skewed data excluded), Outcome 1 Mental State: 1. General Mental State: PANSS total score (high=poor).
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Addington 2004 {published data only}
    1. Addington D, Pantelis C, Benattia I. Ziprasidone vs risperidone in schizophrenia: efficacy and safety in an 8‐week trial. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S125.
    1. Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8‐week, double‐blind, multicenter trial. Journal of Clinical Psychiatry 2004;65(12):1624‐33. - PubMed
Breier 2005 {published data only}
    1. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Roychowdhury SM, Kane JM. Olanzapine Versus Ziprasidone: Results of a 28‐Week Double‐Blind Study in Patients With Schizophrenia. American Journal of Psychiatry 2005;162:1879‐1887. - PubMed
    1. Phillips GA, Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. Journal of Clinical Psychiatry 2006;67(9):1397‐403. - PubMed
Kinon 2006 {published data only}
    1. Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher‐Svanum H, Siris SG. A 24‐week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. Journal of Clinical Psychopharmacology 2006;26(2):157‐62. - PubMed
Lieberman 2005 {published data only}
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209‐23. - PubMed
Olie 2006 {published data only}
    1. Olie JP, Spina E, Benattia I. Ziprasidone vs amisulpride for negative symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S313.
    1. Olie JP, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12‐week, double‐blind study. International Clinical Psychopharmacology 2006;21(3):143‐51. - PubMed
Sacchetti 2006 {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double‐blind 18‐week trial. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double‐blind, 18‐week trial. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S374.
Simpson 2004 {published data only}
    1. Harvey PD, Bowie C, Loebel AD. Long‐term cognitive improvement: ziprasidone versus olanzapine:. Proceeding of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1‐6; New York, USA. New York: American Psychiatric Association, 2004.
    1. Harvey PD, Bowie CR, Loebel A, Warrington L. Cognitive improvement and neuropsychological normalization with ziprasidone or olanzapine: Results of a 6‐month study. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S294.
    1. Harvey PD, Siu CO, Romano S. Randomized, controlled, double‐blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology 2004;172(3):324‐32. - PubMed
    1. Masand PS, Loebel AD. Analysis of remission in a six‐month double‐blind continuation study of ziprasidone versus olanzapine. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
    1. Meyer J, Nasrallah H, Loebel A, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6‐week randomized study in patients with acute schizophrenia. Proceedings of the Collegium Internationale Neuro‐Psychopharmacologium 25th Biennial Congress; 2006 July 9‐13; Chicago, Illinois. Chicago: Internationale Neuro‐Psychopharmacologium, 2006.
Stroup 2006 {published data only}
    1. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163(4):611‐22. - PubMed
Svestka 2005 {published data only}
    1. Svestka J. Comparison of olanzapine versus ziprasidone in acute schizophrenia. Psychiatrie Prague 2005;9:4.

References to studies excluded from this review

Ascher‐Svanum 2006 {published data only}
    1. Ascher‐Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8. - PMC - PubMed
Baloescu 2006 {published data only}
    1. Baloescu A, Vasile D, Gheorghe MD, Grigorescu G. Side effects of atypical antipsychotics ‐ prediction factor for compliance. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S403.
Hagger 1997 {published data only}
    1. Hagger C, Mitchell D, Wise AL, Schulz SC. Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data. Proceedings of the10th European College of Neuropsychopharmacology Congress; 1997 Sep 13‐17; Vienna, Austria. Vienna: Neuropsychopharmacology, 1997.
Harrigan 2004 {published data only}
    1. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology 2004;24(1):62‐9. - PubMed
Harrison 2004 {published data only}
    1. Harrison D, Leaderer M, Loebel A, Murray S. Ziprasidone vs. Olanzapine: change in coronary heart disease risk during a 6‐week trial. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10‐13; Florence, Italy. Florence: World Psychiatric Association, 2004.
Swanson 2006 {published data only}
    1. Swanson JW, Swartz MS, Dorn RA. Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20‐25; Toronto, Canada. Toronto: American Psychiatric Association, 2006.
Tang 2005 {published data only}
    1. Tang B, Lu Z, Zhou Z. A control study of ziprasidone vs clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2005;11(4):303‐4.
Tudor 2006 {published data only}
    1. Tudor C, Ungureanu D, Gheorghe MD. Olanzapine versus ziprasidone in parenteral administration in psychotic relapse of schizophrenia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S397.
Uzun 2002 {published data only}
    1. Uzun S, Folnegovic‐Smalc V, Mimica N, Ljubin T, Makaric G, Ivezic S, Jelacic P, Vilibic M, Markan‐Sosic V. Ziprasidone clinical trials conducted in Croatia. Schizophrenia Research 2002;53(3 Suppl 1):182.

References to studies awaiting assessment

A1281039 {published data only}
    1. A1281039. double blind, double‐dummy multicenter, parallel group comparison of the efficacy and the tolerability of ziprasidone vs. Clozapine in schizophrenic patients who are refractory and/or intolerant to antipsychotic therapy. ClinicalStudyResults.org 2006.
ACTRN12610000954022 {published data only}
    1. ACTRN12610000954022. An open randomised clinical trial involving haloperidol, olanzapine, quetiapine, risperidone, and ziprasidone in first episode never‐treated psychosis. http://www.anzctr.org.au 2010.
Addington 2004a {published data only}
    1. Addington D, Pantelis C, Dineen M, Loebel A, Murray S, Dunn J. Ziprasidone vs risperidone in schizophrenia: 52 weeks’ comparison. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Addington 2009 {published data only}
    1. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long‐term treatment of schizophrenia: a 44‐week, double‐blind, continuation study. Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie] 2009;54(1):46‐54. [MEDLINE: ] - PubMed
Agid 2010 {published data only}
    1. Agid O, Siu C, Vanderburg D, Pappadopulos E, Brambilla C, Kapur S. Scoring algorithm for predicting long‐term global functioning in patients with schizophrenia. Schizophrenia Research 2010;117(2‐3):256‐7.
Allison 2007 {published data only}
    1. Allison D, Loebel A, Lombardo I, Siu C. Effect of regression to the mean on drug‐induced weight change. Schizophrenia Bulletin 2007;33(2):418.
Anon 2002 {published data only}
    1. Anon. New Antipsychotic, new benefits?. Current Drug Discovery 2002:11.
Baldacara 2011 {published data only}
    1. Baldacara L, Sanches M, Cordeiro DC, Jackoswski AP. Rapid tranquilization for agitated patients in emergency psychiatric rooms: A randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone. Revista Brasileira de Psiquiatria 2011;33(1):30‐9. [MEDLINE: ] - PubMed
Beuzen 2005 {published data only}
    1. Beuzen J‐N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al. Broad effectiveness trial with aripiprazole in Europe Eu‐Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2‐6; Munich, Germany. 2005.
Beuzen 2006 {published data only}
    1. Beuzen J‐N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al. Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006.
Breier 2005a {published data only}
    1. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of a 28‐week double‐blind study in patients with schizophrenia. American Journal of Psychiatry 2005;162(10):1879‐87. - PubMed
Caroff 2011 {published data only}
    1. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: Implications of the catie schizophrenia trial. Neurologic Clinics 2011;29(1):127‐48. - PMC - PubMed
CATIE {published data only}
    1. Addington D. Impact of second generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14‐18; Honolulu, Hawaii. 2011. - PMC - PubMed
    1. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. Impact of second‐generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Journal of Clinical Psychiatry 2011;72(1):75‐80. [MEDLINE: ] - PMC - PubMed
    1. Adkins DE, Khachane AN, McClay JL, Aberg K, Bukszar J, Sullivan PF, et al. Snp‐based analysis of neuroactive ligand‐receptor interaction pathways implicates pge2 as a novel mediator of antipsychotic treatment response: Data from the catie study. Schizophrenia Research 2012;135(1‐3):200‐1. - PMC - PubMed
    1. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B. Genome‐wide association study of antipsychotic‐induced parkinsonism severity among schizophrenia patients. Psychopharmacology 2009;206(3):491‐9. - PubMed
    1. Bick P, Knoesen N, Castle D. Clinical implications of the CATIE schizophrenia trials: day‐to‐day management lessons for Australasian psychiatrists. Australasian Psychiatry 2007;15(6):465‐9. [MEDLINE: ] - PubMed
ChiCTR‐TRC‐10000934 {published data only}
    1. ChiCTR‐TRC‐10000934. Pharmacogenomic study of schizophrenia. http://www.chictr.org/ 2010.
Dunn 2005 {published data only}
    1. Dunn J, Harrison DJ, Cheli A, Loebel A, Murray S. Ziprasidone vs olanzapine: change in CHD risk during a 6‐week trial. Proceedings of the 13th Association of European Psychiatrists Congress; 2005 Apr 2‐6; Munich, Germany. 2005.
Eng 2008 {published data only}
    1. Eng SM, Strom BL, Faich G, Reynolds RF, D’Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone vs. olanzapine in real‐world use: the ziprasidone observational study of cardiac outcomes (ZODIAC). Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008.
EUFEST {published data only}
    1. Boter H. The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens. http://www.controlled‐trials.com 2005.
    1. Boter H, Derks EM, Fleischhacker WW, Davidson M, Kahn RS, Grp ES. Generalizability of the results of efficacy trials in first‐episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). Journal of Clinical Psychiatry 2010;71(1):58‐65. [MEDLINE: ] - PubMed
    1. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first‐episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 2009;115(2‐3):97‐103. [MEDLINE: ] - PubMed
    1. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. "Cognitive effects of antipsychotic drugs in first‐episode schizophrenia and schizophreniform disorder: a randomized, open‐label clinical trial (EUFEST)": correction. American Journal of Psychiatry 2009;166(6):731. - PubMed
    1. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first‐episode schizophrenia and schizophreniform disorder: a randomized, open‐label clinical trial (EUFEST). American Journal of Psychiatry 2009;166(6):675‐82. [MEDLINE: ] - PubMed
Fahnestock 2007 {published data only}
    1. Fahnestock P, Haupt D, Schweiger J, Westerhaus E, Stevens A, Flavin K, et al. Feasibility of quantifying activity energy expenditure and caloric intake by doubly‐labeled water in treated patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):498‐9.
Fleischhacker 2009 {published data only}
    1. Fleischhacker WW. Safety and tolerability of first and second generation antipsychotics. Proceedings of the World Psychiatric Association International congress; 2009 April 1‐4th; Florence Italy. 2009.
Geng 2008 {published data only}
    1. Geng Y‐C, Geng S‐X. A control study of olanzapine and ziprasidone in the treatment of adolescent schizophrenia [奥氮平与齐拉西酮治疗青少年精神分裂症疗效的对比研究]. 中国医药指南 2008;6(18):60‐1.
Goldstein 2007 {published data only}
    1. Goldstein D. The genetics and pharmacogenetics of neurocognition in patients with schizophrenia. Schizophrenia Bulletin 2007;33(2):299.
Gong 2008 {published data only}
    1. Gong D. The clinical study of ziprasidone in treatment of first ‐ episode schizophrenia [齐拉西酮治疗首发精神分裂症临床研究]. 中国现代医药杂志 2008;10(6):61‐4.
Gouzoulis‐Mayfrank 2006 {published data only}
    1. Gouzoulis‐Mayfrank E. Efficacy and tolerability of ziprasidone versus clozapine in the treatment of dually diagnosed (dd‐) patients with schizophrenia and cannabis use disorder: a randomised study. http://www.controlled‐trials.com 2006. - PubMed
Grootens 2009 {published data only}
    1. Grootens K, Veelen N, Sitskoom M, Verkes RJ, Kahn R. Effects of olanzapine and ziprasidone on cognitve outcome in recent‐onset schizophrenia. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15‐18; Barcelona, Spain. 2009.
Grootens 2010 {published data only}
    1. Grootens KP, Veelen NMJ, Sitskoorn MM, Sabbe BGC, Peuskens J, Buitelaar JK, et al. Effects on cognitive functioning after olanzapine‐ziprasidone crossover in recent‐onset schizophrenia. European Neuropsychopharmacology 2010;20(12):907‐12. - PubMed
Grootens 2011 {published data only}
    1. Grootens KP, Veelen NMJ, Peuskens J, Sabbe BGC, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent‐onset schizophrenia and schizoaffective disorder: Results of an 8‐week double‐blind randomized controlled trial. Schizophrenia Bulletin 2011;37(2):352‐61. - PMC - PubMed
Harrison 2004a {published data only}
    1. Harrison D, Mackell J, Leaderer M. Ziprasidone versus olanzapine: changes in CHD risk during a 6‐week trial. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Harvey 2004 {published data only}
    1. Harvey PD, Cohen GM, Loebel A. Ziprasidone versus olanzapine in schizophrenia: 6‐month cognitive data. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Harvey 2007 {published data only}
    1. Harvey PD, Galluzzo A, Sachetti E, Romeo F, Warrington L. Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double‐blind comparative study. Schizophrenia Bulletin 2007;33(2):560.
Harvey 2007a {published data only}
    1. Harvey P, Warrington L, Loebel A, Romeo F, Gorini B, Galluzzo A, et al. Cognitive effects of ziprasidone and clozapine: results from an 18‐week double‐blind trial. European Neuropsychopharmacology 2007;17(Suppl 4):S439.
Harvey 2007b {published data only}
    1. Harvey PD, Warrington L, Loebel AD, Romeo F, Gorini B, Galluzzo A, et al. Cognitive effects of ziprasidone and clozapine in treatment‐resistant schizophrenia: results from an 18‐week double‐blind trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA 2007.
Harvey 2008 {published data only}
    1. Harvey PD, Sacchetti E, Galluzzo A, Romeo F, Gorini B, Bilder RM, et al. A randomized double‐blind comparison of ziprasidone vs clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia Research 2008;105(1‐3):138‐43. - PubMed
Houston 2004 {published data only}
    1. Houston JP, Kaiser CJ, Ahl J, Berg PH, Ahmed S, Carlson C, et al. A comparison of the reduction of agitation in schizophrenic patients treated with olanzapine vs. ziprasidone in a 28‐week double‐blind study. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Jiang 2008 {published data only}
    1. Jiang C. Observation of therapeutic effect of zipraside in the treatment of chronic schizophrenia [齐拉西酮治疗慢性精神分裂症的疗效观察]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2008;16(12):1389‐90.
Jiang 2008a {published data only}
    1. Jiang C, Wang G. The clincal study on ziprasidone and risperidone in the treatment of patients with first‐onset schizophrenia [齐拉西酮与利培酮治疗首发精神分裂症疗效的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2008;21(3):212‐3.
Johnsen 2009 {published data only}
    1. Johnsen E, Kroken RA, Wentzel‐Larsen T, Jorgensen HA. A practical, randomized comparison of the effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA 2009.
Johnsen 2010 {published data only}
    1. Johnsen E, Kroken RA, Wentzel‐Larsen T, Jorgensen HA. Effectiveness of second‐generation antipsychotics: A naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 2010;10:26. [MEDLINE: ] - PMC - PubMed
Johnsen 2010a {published data only}
    1. Johnsen E, Kroken RA, Jorgensen HA. Anti‐depressive effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone: A randomized, naturalistic study. Schizophrenia Research 2010;117(2‐3):377‐78. [MEDLINE: ]
Johnsen 2011 {published data only}
    1. Johnsen E, Jorgensen HA, Kroken RA, Loberg EM. Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: A pragmatic, randomized trial. European Psychiatry 2011 Dec 6 [Epub ahead of print]. [MEDLINE: ] - PubMed
Kane 2010 {published data only}
    1. Kane JM, Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, et al. Primary and readjudication mortality results from zodiac, a large simple trial of ziprasidone vs. olanzapine in patients with schizophrenia. Schizophrenia Research 2010;117(2‐3):183‐4.
Keefe 2008 {published data only}
    1. Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12‐week, randomized, double‐blind, placebo‐controlled trial. Neuropsychopharmacology 2008;33(6):1217‐28. [MEDLINE: ] - PubMed
Kinon 2004 {published data only}
    1. Kinon BJ, Lipkovich I, Carlson C, Dunayevich E, Edwards SB. Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Kjelby 2011 {published data only}
    1. Kjelby E, Jorgensen HA, Kroken RA, Loberg EM, Johnsen E. Anti‐depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: A pragmatic, randomized trial. BMC Psychiatry 2011;11(1):145. [MEDLINE: ] - PMC - PubMed
Kuwilsky 2010 {published data only}
    1. Kuwilsky A, Krumm B, Englisch S, Dressing H, Zink M. Long‐term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43(6):216‐20. - PubMed
Li 2007 {published data only}
    1. Li H. Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia [阿立哌唑和齐拉西酮治疗精神分裂症的临床比较]. International Medicine and Health Guidance News [国际医药卫生导报] 2007;13(11):77‐9.
Li 2007a {published data only}
    1. Li X‐L, Lu X‐B, Zheng S‐Y. Olanzapine and ziprasidone in the treatment of schizophrenia [奥氮平与齐拉西酮治疗精神分裂症的对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2007;20(3):157‐8.
Liang 2007 {published data only}
    1. Liang S. Control study of ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. China Pharmaceuticals [中國藥業] 2007;16(17):52.
Liu 2008 {published data only}
    1. Liu X, Jia J. Comparative study on ziprasidone and risperidone in the treatment of schizophrenia patients [齐拉西酮和利培酮治疗精神分裂症的对照研究]. Journal of the Binzhou Medical College 2008;31(2):119‐20.
Liu 2008a {published data only}
    1. Liu W, Zhang X. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms [齐拉西酮与阿立哌唑治疗以阴性症状为主的精神分裂症对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2008;16(2):124‐5.
Loza 2011 {published data only}
    1. Loza B, Patejuk‐Mazurek I, Polikowska M, Bednarski P, Mosiolek A, Kwasna J, et al. Crossover comparison of serum glycemia variability of intramuscular forms of antipsychotics: Aripiprazole, olanzapine and ziprasidone. European Neuropsychopharmacology 2011;21(Suppl 3):S499‐500. [MEDLINE: ]
Lu 2007 {published data only}
    1. Lu C. Comparative study of ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与维思通治疗精神分裂症的对照研究]. 青岛医药卫生 2007;39(5):336‐7.
Lu 2008 {published data only}
    1. Lu X, Wang J‐L. Comparing ziprasidone and olanzapine in treatment of schizophrenia [齐拉西酮与奥氮平治疗首发精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(5):335‐6.
Lublin 2009 {published data only}
    1. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12‐week open‐label, multicentre clinical trial. World Journal of Biological Psychiatry 2009;10(4 Pt 3):710‐8. - PubMed
Meyer 2005 {published data only}
    1. Meyer J, Loebel A, Nasrallah H. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6‐week randomized study in patients with acute schizophrenia. Neuropsychopharmacology 2005;30(Suppl 1):S202‐3.
Meyer 2006 {published data only}
    1. Meyer J, Nasrallah H, Loebel A, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6‐week randomized study in patients with acute schizophrenia. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006.
Meyer 2006a {published data only}
    1. Meyer J, Loebel A, Nasrallah H, Templeton HB. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6‐week randomized study in patients with acute schizophrenia. Biological Psychiatry 2006;59(8 Suppl):159S.
Meyer 2006b {published data only}
    1. Meyer J, Loebel A, Nasrallah H, Parsons B. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: Results of a 6‐week randomized study in patients with acute schizophrenia. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. Davos, SWITZERLAND: Elsevier Science Bv, 2006:93.
Murray 2003 {published data only}
    1. Murray SR, Addington DE, Pantelis C, Dineen M, Romano SJ. Ziprasidone versus risperidone in schizophrenia: a 52 weeks' comparison. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco, California, USA. 2003:1.
Nai 2008 {published data only}
    1. Nai X‐Z, Shi L, Song C‐L, Zhao S‐F. Comparative study on ziprasidone and risperidone in treating first episode schizophrenia [齐拉西酮与利培酮治疗首发精神分裂症对照研究]. Journal of the Henan Medical College for Staff and Workers 2008;20(3):226‐8.
NCT00077727 {published data only}
    1. NCT00077727. A study of galantamine hbr as an adjunctive treatment to atypical antipsychotic medications in outpatients with schizophrenia and associated cognitive deficits. http://www.clinicaltrials.gov 2004.
NCT00145444 {published data only}
    1. NCT00145444. A multicenter, double‐blind, randomized trial of ziprasidone (80 ‐ 160 mg) versus olanzapine (10 ‐ 20 mg) in patients with recent‐onset schizophrenia, schizoaffective and schizophreniform disorder. http://www.clinicaltrials.gov 2005.
NCT00148564 {published data only}
    1. NCT00148564. Energy homeostasis and metabolism in patients with schizophrenic disorders under treatment with atypical antipsychotics. http://www.clinicaltrials.gov 2005.
NCT00159770 {published data only}
    1. NCT00159770. Tolerability, safety, and efficacy of ziprasidone (80 ‐ 160 mg/d) versus olanzapine (10 ‐ 20 mg/d), risperidone (4 ‐ 8 mg/d) or quetiapine (300 ‐ 750 mg/d) in pretreated patients with schizophrenia, schizoaffective disorder or schizophreniform disorders ‐ a 12‐week open‐label, multicenter clinical trial. http://www.clinicaltrials.gov 2005.
NCT00224315 {published data only}
    1. NCT00224315. Clozapine‐augmentation with ziprasidone or risperidone, a randomized, prospective trial. http://www.clinicaltrials.gov 2005.
NCT00225498 {published data only}
    1. NCT00225498. Neurocognitive effects of ziprasidone: relationship to working memory and dopamine blockade. http://www.clinicaltrials.gov 2005.
NCT00239109 {published data only}
    1. NCT00239109. Ziprasidone versus olanzapine in the treatment of schizophrenia: a six months, double blind randomized, parallel group study. http://www.clinicaltrials.gov 2005.
NCT00283179 {published data only}
    1. NCT00283179. Efficacy and safety of aripiprazole in the treatment of acutely relapsed patients with schizophrenia or schizoaffective disorder with risperidone as an active control. http://www.clinicaltrials.gov 2006.
NCT00418171 {published data only}
    1. NCT00418171. An international, multicenter, large simple trial (LST) to compare the cardiovascular safety of ziprasidone and olanzapine. http://www.clinicaltrials.gov 2007.
NCT00515723 {published data only}
    1. NCT00515723. Glucose and lipid metabolism on antipsychotic medication. http://www.clinicaltrials.gov 2007.
NCT00634348 {published data only}
    1. NCT00634348. A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov 2008.
NCT00645372 {published data only}
    1. NCT00645372. A study to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients. http://www.clinicaltrials.gov 2008.
NCT00645515 {published data only}
    1. NCT00645515. A study comparing the safety and efficacy of ziprasidone and risperidone for the treatment of chronic schizophrenia. http://www.clinicaltrials.gov 2008.
NCT00649844 {published data only}
    1. NCT00649844. A study comparing the efficacy and tolerability of ziprasidone vs clozapine for the treatment of schizophrenia in patients who continue to have symptoms on or cannot tolerate other antipsychotic drugs. http://www.clinicaltrials.gov 2008.
NCT00932529 {published data only}
    1. NCT00932529. Use, effects and side‐effects of second‐generation antipsychotics in a naturalistic setting. http://www.clinicaltrials.gov 2009.
Newcomer 2009 {published data only}
    1. Newcomer JW, Haupt DW, Fahnestock PA, Flavin KS, Nicol GE, Schweiger JA, et al. Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA 2009.
Newcomer 2009a {published data only}
    1. Newcomer JW, Haupt D, Fahnestock P, Flavin K, Nicol G, Schweiger J, et al. Changes in adiposity, insulin sensitivity and lipid metabolism during randomized antipsychotic treatment in schizophrenia. Proceedings of the 12th International Congress on Schizophrenia Research; 2009 Mar 28‐Apr 1; San Diego, CA. San Diego, CA: Oxford Univ Press, 2009:361‐2.
Nie 2007 {published data only}
    1. Nie S‐C, Zhang Y‐C, Dai M‐Z. A comparative study of ziprasidone and clozapine in treating schizophrenia [齐拉西酮与氯氮平治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(11):952‐3.
Olfson 2011 {published data only}
    1. Olfson M, Ascher‐Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatric Services 2011;62(10):1138‐45. [MEDLINE: ] - PubMed
Parsons 2008 {published data only}
    1. Parsons B, Zhang H, Shu L, Li H, Gu N, Wang G, et al. double‐blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. - PMC - PubMed
Pfizer 2005 {published data only}
    1. Pfizer. Effects of ziprasidone (80 ‐ 160 mg/d) versus olanzapine (10‐20 mg/d) on cognitive function in patients with schizophrenia or schizophrenic disorder previously treated with a typical neuroleptic drug (fluphenazine) ‐ multicenter, randomized, double‐blind (double‐dummy), comparative study over 4 weeks with an open‐label ziprasidone extension phase of up to one year. http://www.clinicalstudyresults.org/ 2005.
Pfizer 2006 {published data only}
    1. Pfizer. Down‐titration schedules of amisulpride in patients suffering from schizophrenia or schizoaffective disorders when initiating therapy with ziprasidone: an open‐label, three‐months study. http://www.clinicalstudyresults.org/ 2006.
Pfizer 2007 {published data only}
    1. Pfizer. A six week, multicenter, double‐blind, double‐dummy, parallel, comparative study to compare the efficacy, safety and tolerability of ziprasidone with risperidone in the treatment of Chinese subjects with acute exacerbation of schizophrenia. ClinicalStudyResults.org 2007.
Rappard 2006 {published data only}
    1. Rappard F, Meyer J, Loebel A, Nasrallah H. Comparative effects of ziprasidone and olanzapine on markers of insulin resistance: results of a 6‐week randomized study in patients with acute schizophrenia. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S287.
Ross 2005 {published data only}
    1. Ross DE. "randomized, controlled, double‐blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder": comment. American Journal of Psychiatry 2005;162(7):1391. - PubMed
Roychowdhury 2004 {published data only}
    1. Roychowdhury SM, Sethuraman G, Phillips GA, Enerson M, Berg PH, Breier A. Comparison of olanzapine to other atypical antipsychotics in preventing relapse in patients with schizophrenia. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update"; 2004 Nov 10‐13; Florence, Italy. 2004.
Sacchetti 2006a {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double‐blind, 18‐week trial. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4‐10; Davos, Switzerland. 2006.
Sacchetti 2006b {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, et al. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double‐blind, 18‐week trial. Biological Psychiatry 2006;59(8 Suppl):158S.
Sacchetti 2006c {published data only}
    1. Sacchetti E, Romeo F, Galluzzo A, Valsecchi P, Gorini B, Warrington L. Comparative efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients: results of a randomized, double‐blind, 18‐week trial. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S274.
Sacchetti 2007 {published data only}
    1. Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L. Comparison of ziprasidone and clozapine in subgroups of patients with treatment‐resistant schizophrenia. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA 2007.
Sacchetti 2007a {published data only}
    1. Sacchetti E, Galluzzo A, Romeo F, Gorini B, Warrington L. Long‐term efficacy of ziprasidone in treatment‐ resistant schizophrenia: results from a 1‐year, open‐label extension study. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19‐24; San Diego, CA 2007.
Sacchetti 2009 {published data only}
    1. Sacchetti E. Efficacy of ziprasidone in the treatment of resistant schizophrenia (organized by Pfizer). World Psychiatry 2009;8(Suppl 1):SME4.
Sacchetti 2009a {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophrenia Research 2009;110(1‐3):80‐9. [MEDLINE: ] - PubMed
Sacchetti 2009b {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study (DOI:10.1016/j.schres.2009.02.017). Schizophrenia Research 2009;113(1):112‐21. [MEDLINE: ] - PubMed
Sacchetti 2009c {published data only}
    1. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. "Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study": corrigendum. Schizophrenia Research 2009;113(1):111. - PubMed
Samochowiec 2009 {published data only}
    1. Samochowiec J, Tybura P, Wysiecka JP. Pharmacogenetic studies of ziprasidone, olanzapine and perazine in paranoid schizophrenia. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16‐21; San Francisco, CA 2009.
Schooler 2011 {published data only}
    1. Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al. Proactive: Initial results of an rct comparing long‐acting injectable risperidone to 2nd generation oral antipsychotics. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4‐8;a, Waikoloa, Hawaii. 2011:S104‐S5.
Schooler 2011a {published data only}
    1. Schooler NR, Buckley PF, Mintz J, Goff DC, Kopelowicz A, Lauriello J, et al. Proactive: Initial results of an rct comparing long‐acting injectable risperidone to 2nd generation oral antipsychotics. Proceedings of the 50th Annual Meeting of the American College of Neuropsychopharmacology; 2011 Dec 4‐8; Waikoloa, Hawaii. 2011.
Shang 2007 {published data only}
    1. Shang X‐Z, Zhu J‐S, Zeng D‐Z, Cheng P, Sun Q‐X, Chen K‐Q. Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照分析]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2007;17(6):392‐3.
Shang 2008 {published data only}
    1. Shang X‐Z, Zeng D‐Z, Zhu J‐S. Influence of ziprasidone on quality on life of patients with schizophrenia [齐拉西酮对精神分裂症患者生活质量的影响]. Chinese Journal of Rehabilitation [中國康復] 2008;23(1):69‐70.
Shuai 2008 {published data only}
    1. Shuai H‐L. Ziprasidone versus risperidone in the treatment of schizophrenia: cost‐effectiveness analysis [齐拉西酮与利培酮治疗精神分裂症成本‐效果分析]. Evaluation and Analysis of Drug‐Use in Hospital of China 2008;8(4):289‐90.
Simpson 2005 {published data only}
    1. Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Correction: "randomized, controlled, double‐blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder". American Journal of Psychiatry 2005;162(3):644. - PubMed
Simpson 2006 {published data only}
    1. Simpson GM, Loebel A, Warrington L, Yang R. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder: results of a double‐blind, six‐week study, with a six‐month, double‐blind, continuation phase. In: Cummings JL editor(s). Progress in Neurotherapeutics and Neuropsychopharmacology. New York, NY, US: Cambridge University Press, 2006:149‐63, xi.
Sonmez 2009 {published data only}
    1. Sonmez B, Vardar E, Altun GD, Abay E, Bedel D. Ziprasidone versus risperidone: comparison of clinical efficacy and cardiac, extrapyramidal, and metabolic side effects in patients with acute exacerbation of schizophrenia and schizoaffective disorders. Bulletin of Clinical Psychopharmacology 2009;19(2):101‐12.
Sramek 2003 {published data only}
    1. Sramek JJ, Cutler NR, Shiovitz T. The effect of antipsychotics on plasma lipids. Journal of Clinical Psychopharmacology 2003;23(6):679‐80. - PubMed
Street 2000 {published data only}
    1. Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, et al. Olanzapine for psychotic conditions in the elderly. Psychiatric Annals 2000;30:191‐6.
Strom 2007 {published data only}
    1. Strom B, Faich G, Reynolds RF, Eng SM, Kane M. Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone. Schizophrenia Bulletin 2007;33(2):462.
Strom 2007a {published data only}
    1. Strom BL, Faich G, Lombardo I, Reynolds RF, Eng SM, Kane JM. Cardiac risk factors and schizophrenia: an analysis of 18,094 patients enrolled in an international comparative trial of olanzapine and ziprasidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28‐Apr 1; Colorado Springs, Colorado, USA 2007.
Strom 2008 {published data only}
    1. Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, et al. The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. Journal of Clinical Psychiatry 2008;69(1):114‐21. [MEDLINE: ] - PubMed
Strom 2010 {published data only}
    1. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. The Ziprasidone Observational Study of Cardiac outcomes (ZODIAC): findings from a large simple trial of ziprasidone vs. Olanzapine in real‐world use among 18154 patients with schizophrenia. Schizophrenia Research 2010;117(2‐3):311.
Strom 2011 {published data only}
    1. Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real‐world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (zodiac). American Journal of Psychiatry 2011;168(2):193‐201. - PubMed
Sun 2007 {published data only}
    1. Sun Q‐X, Zeng D‐Z, Chen K‐Q. Clinical comparative study of ziprasidone in the treatment of schizophrenia [齐拉西酮治疗精神分裂症临床对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2007;20(3):150‐1.
Svestka 2005a {published data only}
    1. Svestka J. Comparison of olanzapine versus ziprasidone in acute schizophrenia [Olanzapin v. ziprasidon v lecbe akutnich exacerbaci schizofrennich a schizoafektivnich poruch]. Psychiatrie Prague 2005;9:4.
Swartz 2007 {published data only}
    1. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164(3):428‐36. [MEDLINE: ] - PubMed
Tao 2008 {published data only}
    1. Tao S‐W, Chen Q, Yang C, Pan R‐D, Pan T‐W, Li L, et al. A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents [4种非典型抗精神病药物对精神分裂症患者脂代谢的影响]. Journal of the Youjiang Medical College for Nationalities 2008;6:927‐30.
Taylor 2007 {published data only}
    1. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence‐Based Mental Health 2007;10(3):76. [MEDLINE: ] - PubMed
Van Brunt 2004 {published data only}
    1. Brunt DL, Namjoshi M, Xu W, Berg PH, Roychowdhury SM, Cavazzoni P, et al. Clinical efficacy and quality of life in a clinical trial comparing olanzapine and ziprasidone. Proceedings of the 12th Biennial Winter Workshop on Schizophrenia; 2004 Feb 7‐13; Davos, Switzerland. 2004.
Van Veelen 2010 {published data only}
    1. Veelen NMJ, Grootens KP, Peuskens J, Sabbe BGC, Salden ME, Verkes RJ, et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophrenia Research 2010;120(1‐3):191‐8. - PubMed
Wang 2007 {published data only}
    1. Wang Y, Guo H, Liu Y. Comparative study on the influence of ziprasidone and clozapine on quality of life in schizophrenic. Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20‐23; Shanghai 2007.
Wang 2008 {published data only}
    1. Wang G‐P, Xie R, Pei G‐X. Comparative study between ziprasidone and risperidone in treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(1):55‐6.
Wang 2008a {published data only}
    1. Wang X‐Q, Zhou H‐X, Zhang Y‐L, Li G, Xie P‐L. A comparison study of ziprasidone and risperidone in treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(1):35‐7.
Wang 2008b {published data only}
    1. Wang L, Guo H, Feng W. Contrast study of treating schizophrenia by ziprasidone and risperidone [齐拉西酮片与利培酮治疗精神分裂症对照研究]. Journal of Medical Forum [医药论坛杂志] 2008;29(1):11‐3.
Warrington 2006 {published data only}
    1. Warrington L, Harvey PD, Galluzzo A, Sachetti E, Romeo F. Cognitive benefits of ziparasidone vs. clozapine in treatment resistant schizophrenia: a randomized double‐blind comparative study. Neuropsychopharmacology 2006;31(Suppl 1):S243.
Wei 2008 {published data only}
    1. Wei Y, Wang X. A comparative study of ziprasidone and risperdone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的疗效对照研究]. Sichuan Mental Health [四川精神卫生] 2008;21(2):94‐6.
Weiden 2008 {published data only}
    1. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Long‐term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33(5):985‐94. [MEDLINE: ] - PubMed
Wolf 2007 {published data only}
    1. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al. A prospective, multicentre, open‐label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU‐BETA). Current Medical Research and Opinion 2007;23(10):2313‐23. [MEDLINE: ] - PubMed
Woodruff 2003 {published data only}
    1. Woodruff P. A phase IIIb, 12 week, muli‐centre, double‐blind, double‐dummy, randomised, parallel group study comparing the effects of ziprasidone (40‐80mg bid) versus olanzapine (5‐20 mg od) on quality of life in the treatment of schizophrenia. National Research Register 2003.
Wu 2012 {published data only}
    1. Wu XL, Wang JH, Hu SH, Tao J. Serum prolactin levels and the acute‐phase efficacy in drug‐naive schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Archives of Psychiatry 2012;22(1):7‐11. - PubMed
Yang 2008 {published data only}
    1. Yang J, Zhu G‐H, Xie J. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia [齐拉西酮与阿立哌唑治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(23):2760‐1.
Yi 2007 {published data only}
    1. Yi Q‐M, Zhang B. A comparative study between ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮和利培酮治疗精神分裂症的对照研究]. Journal of the North Sichuan Medical College 2007;22(4):328‐30.
Yue 2010 {published data only}
    1. Yue W, Zhang D. Pharmacogenomic study of schizophrenia. http://www.chictr.org/ 2010.
Zhang 2008 {published data only}
    1. Zhang W‐M. Contrast study of treating schizophrenia by ziprasidone, clozapine and risperidone [齐拉西酮与氯氮平、利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(11):1122‐4.
Zhang 2008a {published data only}
    1. Zhang X, Zhang J. A comparative study on the efficacy of ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗首发精神分裂症疗效对照分析]. Shandong Archives of Psychiatry [山东精神医学] 2008;21(5):367‐9.
Zhang 2008b {published data only}
    1. Zhang S‐J, Wang M‐J, Hu J. Comparative analysis between ziprasidone and risperidone in treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(17):2002, 2004.
Zhang 2011 {published data only}
    1. Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al. double‐blind comparison of ziprasidone and risperidone in the treatment of chinese patients with acute exacerbation of schizophrenia. Neuropsychiatric Disease and Treatment 2011;7:77‐85. [MEDLINE: ] - PMC - PubMed
Zhao 2008 {published data only}
    1. Zhao L‐P, Wang J‐C. A comparative study between ziprasidone and clozapine in the treatment of patients with schizophrenia [齐拉西酮与氯氮平治疗首发精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(5):403‐4.
Zhu 2010 {published data only}
    1. Zhu H. Ziprasidone and clozapine in treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(1):16‐7.
Zimbroff 2007 {published data only}
    1. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double‐blind, 4‐week study. International Clinical Psychopharmacology 2007;22(6):363‐70. [MEDLINE: ] - PubMed
Zink 2009 {published data only}
    1. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. Journal of Psychopharmacology 2009;23(3):305‐14. [MEDLINE: ] - PubMed
Zou 2008 {published data only}
    1. Zou X‐H, Zhou Y‐F, He L‐Y, Jin Y, Rong W. A comparative study of ziprasidone and olanzapine in schizophrenia with predominantly negative symptoms [齐拉西酮与奥氮平治疗以阴性症状为主的精神分裂症对照研究]. Strait Pharmaceutical Journal 2008;20(3):87‐9.
任列, 2009 {published data only}
    1. 任列, 朱毅平, 孙菊水. 30 cases of ziprasidone in combination with low‐dose clozapine treatment of refractory schizophrenia [齐拉西酮联合小剂量氯氮平治疗难治性精神分裂症30例]. Herald of Medicine [医药导报] [醫藥導報] 2009;28(7):872‐4.
何文刚 2011 {published data only}
    1. 何文刚. Ziprasidone, and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的比较]. 中国医药指南 2011;9(20):50‐2.
兰庆榜 2011 {published data only}
    1. 兰庆榜, 黄海燕, 陶世武. Three kinds of atypical antipsychotic drugs on the ECG of patients with schizophrenia [3种非典型抗精神病药对精神分裂症患者心电图的影响]. 临床精神医学杂志 2011;21(04):267‐9.
冉昌华 2011 {published data only}
    1. 冉昌华. Ziprasidone, and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. 中外医学研究 2011;9(27):124.
冒雷明 2010 {published data only}
    1. 冒雷明. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. 南通大学学报(医学版) 2010;30(4):311‐2.
冯龙喜 2010 {published data only}
    1. 冯龙喜, 刘建华, 李娟, 杨美娟, 张卫华. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2010;20(2):106‐8.
刘国雄 2007 {published data only}
    1. 刘国雄, 阳琼, 薛士健, 蔡颖莲, 李爱凤. A controlled study of domestic ziprasidone and risperidone in the treatment of schizophrenia [国产齐拉西酮与维思通治疗精神分裂症的对照研究]. International Medicine and Health Guidance News [国际医药卫生导报] 2007;13(7):48‐51.
刘忠 2009 {published data only}
    1. 刘忠, 王立娟, 李丽. Quetiapine and ziprasidone on the impact of ECG qtc [奎硫平及齐拉西酮对心电图qtc影响的研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009;17(11):1302‐3.
刘晓红 2008 {published data only}
    1. 刘晓红, 李卫军. Ziprasidone and risperidone in the treatment of 60 female patients with schizophrenia [齐拉西酮与利培酮治疗60例女性精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(23):2778, 2780.
刘洪秋 2010 {published data only}
    1. 刘洪秋, 严明, 毛星. Ziprasidone and risperidone in the treatment of Schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. Jilin Medical Journal 2010;31(22):3636‐7.
刘琼华 2011 {published data only}
    1. 刘琼华. Pharmacoeconomic analysis of clinical four antipsychotic treatment of schizophrenia [临床常用四种抗精神病药治疗精神分裂症的药物经济学分析]. 中国当代医药 2011;18(21):182‐201.
单美艳 2009 {published data only}
    1. 单美艳. Ziprasidone and risperidone in the treatment of schizophrenia double‐blind controlled study [齐拉西酮与利培酮治疗精神分裂症双盲对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2009;22(1):55‐6.
卢殿军 2011 {published data only}
    1. 卢殿军, 宁洁, 吴胜. Ziprasidone and quetiapine in the treatment of schizophrenia and security [齐拉西酮与奎硫平治疗精神分裂症的疗效与安全性比较]. 中国药业 2011;20(15):75‐6.
卢殿军 2011a {published data only}
    1. 卢殿军, 宁洁, 吴胜. The treatment of schizophrenia, the efficacy and safety of ziprasidone hydrochloride [盐酸齐拉西酮与利醅酮治疗精神分裂症的疗效及安全性比较]. 重庆医学 2011;40(17):1693‐4.
吴远芳 2008 {published data only}
    1. 吴远芳. Control study observed 50 cases of the treatment of youth schizophrenia [齐拉西酮治疗青春型精神分裂症50例对照研究观察]. 兵团医学 2008;16(2):47‐9.
周云 2009 {published data only}
    1. 周云. Ziprasidone and clozapine in the treatment of the negative symptoms of schizophrenia research [齐拉西酮与氯氮平治疗精神分裂症阴性症状研究]. Modern Research of Integrated Chinese and Western Medicine [现代中西医结合杂志] 2009;18(18):2142‐3.
周海晓 2009 {published data only}
    1. 周海晓, 丁志杰, 王军, 王小全. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;19(3):190‐1.
喻志敏 2010 {published data only}
    1. 喻志敏, 邱育平, 张业祥. Ziprasidone and aripiprazole the efficacy and safety of the treatment of schizophrenia [齐拉西酮与阿立哌唑治疗精神分裂症疗效和安全性比较]. 实用临床医学 2010;11(10):17‐20.
孙付根 2009 {published data only}
    1. 孙付根, 董瑞兰, 王云, 马敬. Ziprasidone for schizophrenia and the effect of quality of life [齐拉西酮对首发精神分裂症患者疗效及生活质量的影响]. Occupation and Health [职业与健康] 2009;25(19):2109‐11.
孙付根 2009a {published data only}
    1. 孙付根, 董瑞兰, 赵峥, 潘苗. Efficacy and adverse reactions of ziprasidone in 30 female patients with schizophrenia [齐拉西酮治疗女性精神分裂症30例的疗效及不良反应]. Chinese Journal of New Drugs and Clinical Remedies [中国新药与临床杂志] 2009;28(5):360‐3.
孙平 2011 {published data only}
    1. 孙平, 殷军波. Ziprasidone and risperidone in the treatment of schizophrenia analysis [齐拉西酮与利培酮治疗精神分裂症对照分析]. 黑龙江医药科学 2011;34(04):16‐7.
孙毅 2008 {published data only}
    1. 孙毅, 邓晓舫. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮和利培酮治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(11):1141‐2.
孙爱民 2010 {published data only}
    1. 孙爱民. Ziprasidone given with Risperdal in the treatment of schizophrenia [卓乐定与维思通治疗精神分裂症对照分析]. Aerospace Medicine 2010;21(3):350.
季林影 2009 {published data only}
    1. 季林影, 刘小花, 吴筱芬. 30 cases of ziprasidone on the quality of life of patients with schizophrenia [齐拉西酮对30例精神分裂症患者生活质量的影响]. China Pharmaceuticals [中國藥業] 2009;18(21):64‐5.
宋新虹 2010 {published data only}
    1. 宋新虹, 杨丽. Ziprasidone and risperidone in the treatment of women with schizophrenia [齐拉西酮与利培酮治疗女性精神分裂症对照研究]. Jilin Medical Journal 2010;31(31):5556‐7.
寇桂敏, 2009 {published data only}
    1. 寇桂敏, 余琳, 吕建华. Ziprasidone and clozapine in the treatment of schizophrenia control study [齐拉西酮与氯氮平治疗首发精神分裂症]. 中国现代药物应用 2009;3(17):10‐12.
屈建新 2008 {published data only}
    1. 屈建新, 边欣丑, 崔春青. Risperidone and ziprasidone on cognitive function in patients with schizophrenia [利培酮和齐拉西酮对精神分裂症患者认知功能的影响]. Hebei Medical Journal 2008;30(10):1505‐6.
崔开艳 2010 {published data only}
    1. 崔开艳, 刘兰芬, 杨丽敏. Ziprasidone and risperidone on prolactin in patients with schizophrenia and body mass, blood glucose, blood lipid [齐拉西酮与利培酮对精神分裂症患者泌乳素及体质量、血糖、血脂的影响]. Shandong Archives of Psychiatry [山东精神医学] 2010;23(1):7‐9.
崔隽, 2007 {published data only}
    1. 崔隽, 黄艳, 黄朝. Domestic ziprasidone treatment of schizophrenia clinical observation [国产齐拉西酮治疗精神分裂症临床观察]. 中国现代医生 2007;45(4):61‐2.
庞良俊 2010 {published data only}
    1. 庞良俊, 杨琪, 谢思思, 朱道明. Ziprasidone and clozapine in the treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2010;20(2):119‐20.
张小智 2010 {published data only}
    1. 张小智, 甘全喜, 阮靖. Ziprasidone and clozapine in the treatment of schizophrenia with negative symptoms associated control study [齐拉西酮与氯氮平联用治疗精神分裂症阴性症状对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(5):568‐9.
张峰 2010 {published data only}
    1. 张峰, 钱秀丽, 贺启元. Change‐control study of ziprasidone and risperidone‐induced weight and metabolic indicators [齐拉西酮与利培酮所致体重及代谢指标变化对照研究]. 中国民康医学 2010;22(22):2840‐75.
张明松 2009 {published data only}
    1. 张明松, 宋丽, 赵艳华, 樊凌姿. Control study of ziprasidone and risperdone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. 中国实用神经疾病杂志 2009;12(13):31‐3.
张玖龙 2010 {published data only}
    1. 张玖龙, 郭新宇, 李美娟. Ziprasidone treatment of schizophrenia with depressive symptoms were observed [齐拉西酮治疗精神分裂症伴抑郁症状对照观察]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2010;20(1):44‐5.
张艳琦 2010 {published data only}
    1. 张艳琦, 于振东. Ziprasidone and clozapine in the treatment of refractory schizophrenia [齐拉西酮与氯氮平治疗难治性精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(5):532‐3.
张香芝 2009 {published data only}
    1. 张香芝, 于俊丽, 孔德荣, 霍军. Ziprasidone treatment of simple type schizophrenia [齐拉西酮治疗单纯型精神分裂症的对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;19(5):320‐1.
张鸿燕, 2010 {published data only}
    1. 张鸿燕, 刘粹, 闫俊, 舒良, 李华芳, 顾牛范, et al. Efficacy and safety of ziprasidone treatment of schizophrenia with acute exacerbation [齐拉西酮治疗精神分裂症急性发作的疗效和安全性]. 中国新药杂志 2010;19(22):2076‐89.
彭亮 2010 {published data only}
    1. 彭亮. Ziprasidone clinical study of treatment of schizophrenia [齐拉西酮治疗精神分裂症的临床研究]. 中外医疗 2010;21:125.
彭汝春 2009 {published data only}
    1. 彭汝春, 刘爱辉. Comparative analysis of ziprasidone risperidone in the treatment of female schizophrenia [齐拉西酮与利培酮治疗女性精神分裂症的比较分析]. Sichuan Mental Health [四川精神卫生] 2009;22(3):168‐70.
徐国洪 2010 {published data only}
    1. 徐国洪. Ziprasidone and olanzapine schizophrenia [齐拉西酮与奥氮平治疗精神分裂症的对照研究]. 中国医药指南 2010;8(3):98‐9.
徐娟 2009 {published data only}
    1. 徐娟, 刘晓梅, 邱大宏, 陈东萍, 黄群明, 郑远松. A randomized, double blind, double dummy parallel controlled study schizophrenia treated with ziprasidone tablets and risperidone orally disintegrating tablets [齐拉西酮与利培酮口腔崩解片治疗首发精神分裂症患者随机、双盲、双模拟平行对照研究]. Chinese Journal of Rehabilitation Theory and Practice [中国康复理论与实践] 2009;15(6):556‐8.
徐松, 2010 {published data only}
    1. 徐松, 谭庆荣, 郭力, 付春安. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Shandong Archives of Psychiatry [山东精神医学] 2010;23(2):87‐9.
徐莉萍 2011 {published data only}
    1. 徐莉萍, 谢永标, 李佑辉. Risperidone sustained release tablets and the ziprasidone treatment of schizophrenia [帕利哌酮缓释片与齐拉西酮治疗精神分裂症对照研究]. 临床精神医学杂志 2011;21(03):174‐6.
方传荣 2010 {published data only}
    1. 方传荣. Ziprasidone and quetiapine in the treatment of women with schizophrenia [齐拉西酮与喹硫平治疗女性精神分裂症的研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(15):1942‐3.
易峰 2010 {published data only}
    1. 易峰, 李金香, 苏旭江, 王志, 过婷. Aripiprazole and ziprasidone in patients with schizophrenia glucose, lipids [阿立哌唑与齐拉西酮对精神分裂症患者血糖、血脂的影响]. 中国药物应用与监测 2010;7(06):330‐4.
朱志高 2010 {published data only}
    1. 朱志高. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Medical Information 2010;8:2196‐7.
李仕军 2010 {published data only}
    1. 李仕军. Ziprasidone and clozapine in the treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症的对照研究]. 中国民康医学 2010;22(22):2841‐2.
李作珍 2010 {published data only}
    1. 李作珍. Ziprasidone and clozapine in patients with first‐episode schizophrenia Comparison of the effects of ECG [齐拉西酮与氯氮平对首发精神分裂症患者心电图影响的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(15):1924‐5.
李启斌 2008 {published data only}
    1. 李启斌, 张雪琳, 韦红日. Ziprasidone and risperidone in the treatment of senile schizophrenia [齐拉西酮与利培酮治疗老年期精神分裂症的对照研究]. Acta Medicinae Sinica [华夏医学] 2008;21(3):440‐2.
李国胜 2010 {published data only}
    1. 李国胜, 陈玉辉. Ziprasidone and olanzapine clinical control study of schizophrenia [齐拉西酮和奥氮平治疗精神分裂症临床对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(11):1358‐9.
李培轩 2010 {published data only}
    1. 李培轩, 周永明, 蔡旭明, 尹继续. Ziprasidone treatment of schizophrenia, randomized, double‐blind controlled study [齐拉西酮治疗精神分裂症随机双盲对照研究]. 临床精神医学杂志 2010;20(06):404‐5.
李春花 2011 {published data only}
    1. 李春花. Ziprasidone merged observation and care of small doses of clozapine treatment of refractory schizophrenia [齐拉西酮合并小剂量氯氮平治疗难治性精神分裂症的观察及护理]. 求医问药(下半月) 2011;9(07):98‐9.
李树敏 2008 {published data only}
    1. 李树敏. Ziprasidone and risperidone in the treatment of chronic schizophrenia [齐拉西酮与利培酮治疗慢性精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(17):2020‐1.
李梁 2009 {published data only}
    1. 李梁, 黄海燕, 陶世武, 陈强, 杨诚, 潘天伟. Three kinds of antipsychotic drugs on glucose metabolism in patients with schizophrenia [3种抗精神病药物对精神分裂症患者糖代谢的影响]. 当代医学 2009;15(24):1‐2.
李轶群 2009 {published data only}
    1. 李轶群. Ziprasidone and clozapine in the treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症对照研究]. Jiangxi Medical Journal [江西医药] 2009;44(2):151‐2.
杨明华, 2011 {published data only}
    1. 杨明华, 杨芳. Controlled study of aripiprazole and ziprasidone treatment of schizophrenia [阿立哌唑与齐拉西酮治疗精神分裂症的对照研究]. 中国医药指南 2011;9(25):242‐3.
杨老虎 2009 {published data only}
    1. 杨老虎, 赵淑敏, 江芹普, 万爱华, 齐国娥. Ziprasidone and risperidone in the treatment of female control study of schizophrenia [齐拉西酮与利培酮治疗女性精神分裂症临床对照研究]. Chinese Journal of Health Psychology [中国健康心理学杂志] 2009;17(10):1156‐8.
杨胜良 2008 {published data only}
    1. 杨胜良. Ziprasidone and risperidone in the treatment of schizophrenia control study [齐拉西酮与利培酮治疗首发精神分裂症的对照研究]. Herald of Medicine [医药导报] [醫藥導報] 2008;27(10):1197‐8.
杨诚, 2010 {published data only}
    1. 杨诚, 陶世武, 陈强, 潘润德, 潘天伟, 李梁, et al. Association study of four kinds of antipsychotics and glucose metabolism in patients with schizophrenia and glycosylated hemoglobin [4种抗精神病药物与精神分裂症患者糖代谢及糖化血红蛋白的关联性研究]. 中国现代医学杂志 2010;20(18):2816‐20.
杨顺才 2008 {published data only}
    1. 杨顺才, 高申荣, 杜见芳. Ziprasidone and risperidone in the treatment of schizophrenia control study [齐拉西酮与利培酮治疗首发精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(5):409‐10.
林卓毅 2009 {published data only}
    1. 林卓毅, 杨孝, 李福球, 苏伟胜. Comparison of health economics ziprasidone, clozapine treatment [齐拉西酮、氯氮平治疗的卫生经济学比较]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;19(2):97‐8.
林敏 2011 {published data only}
    1. 林敏, 童寿明. Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. 中国民康医学 2011;23(14):1708‐24.
段武刚 2010 {published data only}
    1. 段武刚, 曾德志, 徐良雄, 祝峰, 商秀珍. Ziprasidone and clozapine in the treatment of female schizophrenia [齐拉西酮和氯氮平治疗女性精神分裂症的疗效比较]. Journal of the Hainan Medical College 2010;16(6):771‐3.
段武钢 2010 {published data only}
    1. 段武钢, 曾德志, 罗建武, 商秀珍. Ziprasidone social function in patients with schizophrenia and quality of life [齐拉西酮对精神分裂症患者社会功能和生活质量的影响]. Chinese Journal of Rehabilitation [中國康復] 2010;25(2):156‐8.
殷月珍 2010 {published data only}
    1. 殷月珍, 黄学军. 80 controls were observed ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症80例对照观察]. 中国民康医学 2010;22(23):3042‐4.
温占红 2011 {published data only}
    1. 温占红. Controlled study of ziprasidone and risperidone in the treatment of women with schizophrenia [齐拉西酮与利培酮治疗女性精神分裂症的对照研究]. 北方药学 2011;8(04):44‐6.
潘天伟 2008 {published data only}
    1. 潘天伟, 黄丽萍. Controlled clinical studies of ziprasidone and clozapine in the treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症的临床对照研究]. Guangxi Medical Journal 2008;30(3):348‐50.
潘文燕 2008 {published data only}
    1. 潘文燕, 林振东, 陈冰容. Ziprasidone impact on the quality of life in patients with schizophrenia [齐拉西酮对精神分裂症患者生活质量的影响]. 中国医药指南 2008;6(13):22‐3.
熊辉 2011 {published data only}
    1. 熊辉, 李洪毅, 王维勇, 彭志. Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia [齐拉西酮与利培酮治疗急性期精神分裂症的随机对照研究]. 检验医学与临床 2011;8(01):9‐13.
王体宾 2011 {published data only}
    1. 王体宾, 孔德荣, 张岩滨, 李峥, 胡雄, 霍军, et al. Comparison of the effects of ziprasidone and clozapine, risperidone on lipid metabolism in patients with schizophrenia [齐拉西酮与氯氮平、利培酮对精神分裂症患者脂代谢影响的对照研究]. 中国实用神经疾病杂志 2011;14(12):1‐3.
王天龙 2008 {published data only}
    1. 王天龙, 程平, 陈红光, 唐鹏, 周桂明. Ziprasidone treatment of schizophrenia with predominantly negative symptoms [齐拉西酮治疗以阴性症状为主精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2008;18(3):206‐7.
王学军 2009 {published data only}
    1. 王学军, 马富晓. Efficacy of ziprasidone treatment of schizophrenia and quality of life [齐拉西酮治疗精神分裂症疗效及生活质量的影响对照观察]. 中国实用医药 2009;4(23):156‐7.
王方国 2010 {published data only}
    1. 王方国, 陈慧芹, 王胜. Ziprasidone and risperidone in the treatment of women with schizophrenia [齐拉西酮与利培酮治疗女性精神分裂症对照研究]. 社区医学杂志 2010;8(1):26‐7.
王永学 2010 {published data only}
    1. 王永学, 张建, 孙梅玲. Ziprasidone and clozapine on cognitive function in patients with schizophrenia [齐拉西酮与氯氮平对精神分裂症患者认知功能的影响]. 中国实用医药 2010;5(36):5‐6.
王秀芳 2011 {published data only}
    1. 王秀芳, 郭红丽, 张洪伟, 吴雪飞, 张建. Aripiprazole and ziprasidone, the prevalence of metabolic syndrome in patients with schizophrenia [阿立哌唑和齐拉西酮对精神分裂症患者代谢综合征患病率的影响]. 医学信息(中旬刊) 2011;6:2570‐1.
王金堂 2010 {published data only}
    1. 王金堂, 尤加永, 常余善. Effective control study of ziprasidone and risperidone in first episode schizophrenia [齐拉西酮与利培酮治疗首发精神分裂症患者疗效对照研究]. 中国民康医学 2010;22(23):2993‐4.
白剑文 2009 {published data only}
    1. 白剑文. Ziprasidone and aripiprazole in the treatment of schizophrenia [齐拉西酮与阿立哌唑治疗精神分裂症对照研究]. 青岛医药卫生 2009;41(3):199‐200.
白锦波 2010 {published data only}
    1. 白锦波, 黄海燕, 陶世武, 潘天伟, 李梁. Three kinds of atypical antipsychotic drugs on lipid metabolism in patients with schizophrenia [3种非典型抗精神病药物对精神分裂症患者脂代谢的影响]. 中国医药指南 2010;8(17):8‐10.
皮玥玥 2010 {published data only}
    1. 皮玥玥. Ziprasidone and risperidone in the treatment of Schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(5):573‐5.
秦捷 2010 {published data only}
    1. 秦捷, 戴新国. Ziprasidone and clozapine on ECG [齐拉西酮和氯氮平对心电图的影响]. 中国民康医学 2010;22(21):2714‐18.
程平 2009 {published data only}
    1. 程平, 王天龙, 陈红光, 唐鹏, 周桂明. Ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms [齐拉西酮与阿立呱唑治疗以阴性症状为主的精神分裂症对照研究]. Journal of the Xianning Medical College [新乡医学院学报] 2009;23(2):106‐8.
程燕 2009 {published data only}
    1. 程燕. Ziprasidone and risperidone in the treatment of schizophrenia in the clinical control study [齐拉西酮与利培酮治疗精神分裂症的临床对照研究]. 中国现代药物应用 2009;3(14):157.
管銮友 2009 {published data only}
    1. 管銮友. Ziprasidone and quetiapine in the treatment of senile schizophrenia [齐拉西酮与奎硫平治疗老年性精神分裂症的对照研究]. Journal of Military Surgeon in Southwest China 2009;11(5):843‐5.
胡华廷 2011 {published data only}
    1. 胡华廷, 高金香. Controlled study of ziprasidone, and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. 中国当代医药 2011;18(20):71‐2.
莫亚莉 2010 {published data only}
    1. 莫亚莉. Ziprasidone treatment of low dose clozapine in refractory schizophrenia 33 patients [齐拉西酮联合小剂量氯氮平治疗难治性精神分裂症33例疗效观察]. Zhejiang Practical Medicine 2010;15(1):43‐5.
董伟 2008 {published data only}
    1. 董伟, 杨翔. Ziprasidone and quetiapine treatment episode schizophrenia [齐拉西酮与喹硫平治疗首发精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(12):1275, 1380.
董伟 2010 {published data only}
    1. 董伟, 顾卫霞. Ziprasidone and risperidone in the treatment of female patients with schizophrenia control study [齐拉西酮与利培酮治疗女性精神分裂症患者疗效的对照研究]. Modern Diagnosis and Treatment 2010;2:77‐8.
董太新 2007 {published data only}
    1. 董太新, 阮江红, 李永芝, 李昱. Ziprasidone in the treatment of first diagnosis of schizophrenia [齐拉西酮治疗首诊精神分裂症临床分析]. Medical Journal of Chinese People's Health [中国民康医学] 2007;19(12):1061.
蔡进伟 2009 {published data only}
    1. 蔡进伟, 季林影. Ziprasidone and risperidone on treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. China Pharmacist 2009;12(3):363‐4.
覃松 2009 {published data only}
    1. 覃松. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照研究]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志] 2009;3:190‐1.
许亚平 2010 {published data only}
    1. 许亚平. Ziprasidone, and risperidone in the treatment of adolescent schizophrenia‐control study [齐拉西酮和利培酮治疗青少年精神分裂症临床对照研究]. 亚太传统医药 2010;6(10):123‐4.
许志平 2008 {published data only}
    1. 许志平, 陈巧平. Ziprasidone and clozapine treatment of schizophrenia [齐拉西酮与氯氮平治疗精神分裂症对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(23):2788, 2793.
谢炜麟 2009 {published data only}
    1. 谢炜麟. The comparative investigation between ziprasidone and risperidone in the treatment of schizophrenia in children [齐拉西酮与利培酮治疗儿童精神分裂症的对照研究]. 国际精神病学杂志 2009;36(3):137‐9.
谢育南 2010 {published data only}
    1. 谢育南, 邝云航, 刘献标, 罗华. Ziprasidone treatment of schizophrenia clinical analysis of 65 cases [齐拉西酮治疗精神分裂症65例的临床分析]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(11):1380‐1.
赵敬平 2010 {published data only}
    1. 赵敬平. Controlled study of ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. 医学信息(中旬刊) 2010;12:3715‐6.
赵明丽 2010 {published data only}
    1. 赵明丽, 常余善. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮和利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(5):559‐61.
赵青霞 2009 {published data only}
    1. 赵青霞, 胡海涛, 张丽霞. Ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照分析]. Journal of Medical Forum [医药论坛杂志] 2009;30(24):72‐4.
邓广 2011 {published data only}
    1. 邓广, 黄焱明. Ziprasidone and aripiprazole improve control study of first episode schizophrenia and social functions [齐拉西酮与阿立哌唑改善首发精神分裂症患者社会功能的对照研究]. 医学信息(上旬刊) 2011;24(07):4219‐20.
邢香然 2011 {published data only}
    1. 邢香然, 张改英. Ziprasidone and aripiprazole treatment of first episode of schizophrenia [齐拉西酮与阿立哌唑治疗首发精神分裂症对照研究]. 基层医学论坛 2011;15(10):929‐30.
郑学宝 2008 {published data only}
    1. 郑学宝, 李金亮, 罗忠, 章旭东. Ziprasidone and risperidone in the treatment of female schizophrenia [齐拉西酮和利培酮治疗女性精神分裂症的临床比较]. Modern Research of Integrated Chinese and Western Medicine [现代中西医结合杂志] 2008;17(20):3110‐1.
郑庆梅 2008 {published data only}
    1. 郑庆梅, 陈巧平, 许志平. Ziprasidone risperdal in the treatment of schizophrenia [齐拉西酮与维思通治疗精神分裂症的对照研究]. 中外医疗 2008;8:46.
钟小兵 2009 {published data only}
    1. 钟小兵, 林志雄. Ziprasidone and olanzapine in schizophrenia [齐拉西酮和奥氮平对精神分裂症的疗效比较]. Journal of the Guangdong Medical College 2009;27(4):434‐5.
阿怀红 2011 {published data only}
    1. 阿怀红, 张发斌. Ziprasidone treatment of female patients with schizophrenia, efficacy and quality of life impact study [齐拉西酮治疗女性精神分裂症患者疗效及生活质量影响研究]. 青海医药杂志 2011;41(05):11‐3.
陆爱益 2009 {published data only}
    1. 陆爱益. Ziprasidone and quetiapine treatment 30 patients in each episode schizophrenia [齐拉西酮与喹硫平治疗首发精神分裂症各30例对照分析]. 内科 2009;4(4):577‐9.
陈恩民 2010 {published data only}
    1. 陈恩民. Ziprasidone Efficacy of first‐episode schizophrenia treatment [齐拉西酮治疗首发精神分裂症疗效观察]. 社区医学杂志 2010;8(15):10‐11.
陈慧 2011 {published data only}
    1. 陈慧. Randomized study of ziprasidone and risperidone in the treatment of acute schizophrenia [齐拉西酮与利培酮治疗急性期精神分裂症的随机对照研究]. 中国医药指南 2011;9(18):111‐3.
陈春梅 2010 {published data only}
    1. 陈春梅. Ziprasidone substitution of female patients with schizophrenia. Risperidone study of the Effect of prolactin [齐拉西酮替换利培酮对女性精神分裂症患者催乳素水平影响的研究]. Nei Moivgol Medical Journal 2010;42(1):38‐9.
雷庆华 2008 {published data only}
    1. 雷庆华, 陈东营, 刘芬, 王艳梅. Control study of ziprasidone and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症的对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(12):1273, 1301.
颜建辉 2011 {published data only}
    1. 颜建辉. Clozapine with ziprasidone capsules with a single controlled clinical study the treatment of schizophrenia with clozapine [氯氮平合并齐拉西酮胶囊与单用氯氮平治疗精神分裂症的临床对照研究]. 中外医学研究 2011;9(24):56‐7.
马兆峰 2009 {published data only}
    1. 马兆峰. The comparation of effects and security of ziprasidone and quetiapine in the treatment of schizophrenia [齐拉西酮与喹硫平治疗精神分裂症疗效和安全性比较]. 山东医学高等专科学校学报 2009;31(3):163‐6.
高星海 2008 {published data only}
    1. 高星海, 万丽莉. Ziprasidone efficacy of cognitive function in patients with chronic schizophrenia [齐拉西酮改善慢性精神分裂症患者认知功能的疗效分析]. Medical Journal of Chinese People's Health [中国民康医学] 2008;20(15):1748‐9.
黄峰 2010 {published data only}
    1. 黄峰. Ziprasidone and risperidone in the treatment of elderly clinical controlled study of schizophrenia [齐拉西酮与利培酮治疗老年精神分裂症的临床对照研究]. Medical Journal of Chinese People's Health [中国民康医学] 2010;22(10):1214‐5.
黄振英 2010 {published data only}
    1. 黄振英, 顾广善. Ziprasidone and quetiapine in the treatment of elderly schizophrenia control analysis [齐拉西酮与喹硫平治疗老年精神分裂症的对照分析]. 中国医药指南 2010;8(35):297‐8.
黄智辉 2011 {published data only}
    1. 黄智辉, 杨立群. Ziprasidone, and risperidone in the treatment of schizophrenia [齐拉西酮与利培酮治疗精神分裂症对照观察]. 中国现代医药杂志 2011;13(06):70‐2.

References to ongoing studies

Mortimer 2001 {published data only}
    1. Mortimer A. A1281014 a phase IIIb, 12 week, multi‐centre, double‐blind, double‐dummy, randomised, parallel group study comparing the effects of ziprasidone versus olanzapine on quality of life in the treatment of schizophrenia and schizoaffective disorder. National Research Register 2001; Vol. 3.
Reveley 2003 {published data only}
    1. Reveley M. MREC/00/1/47 a phase IIIb multicentre randomised double‐blind trial of ziprasidone vs olanzapine in schizophrenia. National Research Register 2003; Vol. 2.

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. - PMC - PubMed
APA 2004
    1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd Edition. American Journal of Psychiatry, 2004:1‐114.
Arnt 1998
    1. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63‐101. - PubMed
Bagnall 2000
    1. Bagnall A, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001945] - DOI - PubMed
Barnes 1989
    1. Barnes TR. A rating scale for drug‐induced akathisia. British Journal of Psychiatry 1989;154:672‐6. - PubMed
Bland 1997
    1. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600. - PMC - PubMed
Boissel 1999
    1. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405‐11. - PubMed
Carpenter 1984
    1. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The quality of life scale an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388‐6. - PubMed
Carpenter 1994
    1. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90. - PubMed
Chouinard 1980
    1. Chouinard G, Ross‐Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Canadian Journal Neurological Sciences 1980;7:233.
Deeks 2000
    1. Deeks J. Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
Divine 1992
    1. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9. - PubMed
Donner 2002
    1. Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80. - PubMed
Duggan 2005
    1. Duggan L, Fenton M, Rathbone J, Dardennes R, El‐Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2] - DOI - PMC - PubMed
Egger 1997
    1. Egger M, Davey‐Smith G, Schneider M, Minder CSO. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;13:629‐34. - PMC - PubMed
El‐Sayeh 2006
    1. El‐Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3] - DOI - PMC - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. [PUBMED: 11914310] - PubMed
Furukawa 2006
    1. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7‐10. - PubMed
Gaebel 2006
    1. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
Gulliford 1999
    1. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83. - PubMed
Guy 1976
    1. Guy 1976. ECDEU assessment for psychopharmacology.. National Institute of Mental Health 1976.
Heres 2006
    1. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185‐94. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2008
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration 2008.
Jones 2006
    1. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second‐ vs first‐generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry 2006;63:1079‐6. - PubMed
Kane 1988
    1. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment‐resistant schizophrenia: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789‐96. [MEDLINE: ] - PubMed
Kane 1993
    1. Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585‐93. - PubMed
Kay 1986
    1. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi‐Health Systems, 1986.
Leucht 2005a
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231‐8. - PubMed
Leucht 2005b
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366‐71. - PubMed
Leucht 2008
    1. Leucht C, Kitzmantel M, Chua L, Leucht S. Haloperidol versus chlorpromazine for treatment of schizophrenia. Schizophrenia Bulletin 2008;34:813‐5. - PMC - PubMed
Liebermann 2005
    1. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209‐23. - PubMed
Marshall 2000
    1. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249‐52. - PubMed
Marvaha 2004
    1. Marvaha S, Johnson S. Schizophrenia and employment ‐ a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337‐49. - PubMed
Moher 2001
    1. Moher D, Schulz KF, Altman D. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA 2001;285:1987‐1. - PubMed
Möller 2000
    1. Möller HJ. New assessment of atypical antipsychotics [Aktuelle Bewertung neuer/atypischer Neuroleptika]. Nervenarzt 2000;71:329‐44. - PubMed
Overall 1962
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Rust 1989
    1. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
Simpson 1970
    1. Simpson EN, Angus JWF. A rating scale for extrapyramidal side‐effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11‐9. - PubMed
Tandon 2008
    1. Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia, "Just the Facts" What we know in 2008. 2. Epidemiology and etiology. Schizophrenia research 2008;102:1‐18. - PubMed
Tsuang 1978
    1. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153‐55. - PubMed
Ukoumunne 1999
    1. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3‐92. - PubMed
WHO 2001
    1. WHO. New understanding, new hope. The world health report 2001‐Mental Health 2001.
Xia 2007
    1. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, Pinfold V, Takriti Y. The Leeds Outcomes Stakeholders Survey (LOSS) Study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23‐27 October 2007. 2007.

References to other published versions of this review

Leucht 2009b
    1. Leucht S, Komossa K, Rummel‐Kluge C, Hunger H, Schmid C, Schwarz S, Asenjo‐Lobos C, Davis JM. A meta‐analysis of head‐to‐head comparisons of second generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166(2):152‐63. - PubMed

MeSH terms